Ryanodine receptor patents

Alexander Kushnir, Andrew R. Marks

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Research over the past two decades has implicated dysfunction of the ryanodine receptor (RyR), a Ca2+release channel on the sarcoplasmic reticulum (SR) required for excitation-contraction (EC) coupling, in the pathogenesis of cardiac and skeletal myopathies. These discoveries have led to the development of novel drugs, screening tools, and research methods. The patents associated with these advances tell the story of the initial discovery of RyRs as a target for plant alkaloids, to their central role in cardiac and skeletal muscle excitation-contraction coupling, and ongoing clinical trials with a novel class of drugs called Rycals™ that inhibit pathological intracellular Ca2+leak. Additionally, these patents highlight questions, controversies, and future directions of the RyR field.

Original languageEnglish (US)
Pages (from-to)157-166
Number of pages10
JournalRecent Patents on Biotechnology
Issue number3
StatePublished - 2012


  • Arrhythmias
  • Calcium
  • Calcium leakage
  • EC-coupling
  • Heart failure
  • JTV519
  • Leaky SR
  • Malignant hyperthermia
  • Myocardium
  • Patents
  • Ryanodine
  • Rycal
  • S107
  • Sarcoplasmic reticulum (SR)
  • Skeletal muscle

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology


Dive into the research topics of 'Ryanodine receptor patents'. Together they form a unique fingerprint.

Cite this